These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22157559)

  • 21. Diagnosis of unknown primary cancer based on molecular techniques may influence therapeutic approach and improve survival.
    Homet B; Hitt R; Ghanem I; Cortés-Funes H
    Clin Transl Oncol; 2010 Aug; 12(8):574-5. PubMed ID: 20709655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Fizazi K; Greco FA; Pavlidis N; Pentheroudakis G;
    Ann Oncol; 2011 Sep; 22 Suppl 6():vi64-8. PubMed ID: 21908507
    [No Abstract]   [Full Text] [Related]  

  • 23. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
    Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.
    Losa F; Iglesias L; Pané M; Sanz J; Nieto B; Fusté V; de la Cruz-Merino L; Concha Á; Balañá C; Matías-Guiu X
    Clin Transl Oncol; 2018 Nov; 20(11):1361-1372. PubMed ID: 29808414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Carcinoma of Unknown Primary on Cytologic Specimens.
    Doxtader EE; Chute DJ
    Surg Pathol Clin; 2018 Sep; 11(3):545-562. PubMed ID: 30190140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetics: CUP: discovering genetic opportunities.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 May; 12(5):251. PubMed ID: 25781575
    [No Abstract]   [Full Text] [Related]  

  • 27. [2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary].
    Matías-Guiu X; Fusté V; Iglesias L; Balañá C; Concha Á; de la Cruz-Merino L; Nieto B; Pané M; Sanz J; Losa F
    Rev Esp Patol; 2019; 52(1):33-44. PubMed ID: 30583830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carcinoma of Unknown Primary Site: The Poster Child for Personalized Medicine?
    Varadhachary G
    JAMA Oncol; 2015 Apr; 1(1):19-21. PubMed ID: 26182299
    [No Abstract]   [Full Text] [Related]  

  • 29. Cancer of unknown primary: from immunohistochemistry to gene expression profiling.
    Chiang WM; Kapadia M; Laver NV; Nystrom JS
    J Clin Oncol; 2012 Oct; 30(29):e300-2. PubMed ID: 22965966
    [No Abstract]   [Full Text] [Related]  

  • 30. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
    Varadhachary G
    Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of patients with cancer of an unknown primary site].
    Enokida T; Ohyama Y
    Gan To Kagaku Ryoho; 2012 May; 39(5):726-30. PubMed ID: 22584324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
    Monzon FA; Medeiros F; Lyons-Weiler M; Henner WD
    Diagn Pathol; 2010 Jan; 5():3. PubMed ID: 20205775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer of unknown primary: changing approaches. A multidisciplinary case presentation from the Joan Karnell cancer center of pennsylvania hospital.
    Mintzer DM; Warhol M; Martin AM; Greene G
    Oncologist; 2004; 9(3):330-8. PubMed ID: 15169988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival?
    Prasad V; Oseran A; Fakhrejahani F
    Eur J Cancer; 2016 Feb; 54():159-162. PubMed ID: 26608119
    [No Abstract]   [Full Text] [Related]  

  • 36. Cancer diagnostics: The journey from histomorphology to molecular profiling.
    Ahmed AA; Abedalthagafi M
    Oncotarget; 2016 Sep; 7(36):58696-58708. PubMed ID: 27509178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What are the expected developments in the medical treatment of bladder cancer.
    Bellmunt J
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S294-7. PubMed ID: 21943989
    [No Abstract]   [Full Text] [Related]  

  • 38. Official nudge toward patient-centric oncology practices.
    Rosenthal ET
    J Natl Cancer Inst; 2012 Aug; 104(16):1201-2. PubMed ID: 22899625
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
    Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
    J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer of unknown primary origin: using ancillary techniques with caution.
    Bhargava R; Dabbs DJ
    J Clin Oncol; 2013 Apr; 31(11):1478-9. PubMed ID: 23439751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.